St George Street Capital is a new type of charity, sourcing investment to fast track clinical trials, so we can get new treatments as quickly as possible to the people who need them.
Thousands of treatments with powerful potential are currently stalled in the system, keeping patients suffering needlessly – sometimes for decades.
Our mission is to apply bold new thinking and lateral approaches to unlock all this therapeutic potential faster and transform the lives of patients and their families.
We don’t expect to achieve a revolution alone. We’re working collaboratively with all kinds of people and organisations in the field, in the UK, US and in China. We want to change the game around existing treatment development. Because we believe when you can change your thinking, you can change the way millions of patients are treated today.
Established in 2017, St George Street Capital brings together a powerful mix of expertise, from investors and business managers to clinical scientists and researchers.
Our key people include:
Chairman. Professor of Cardiovascular Medicine, University College Medicine.
Trustee. Professor of Ocular Biology and Therapeutics, UCL Institute of Ophthalmology.
Trustee. Clinical Pharmacologist and Consultant Physician.
Head of Strategy and Operations.
Head of Clinical Development.
Elin Haf Davies
Consultant. Great Ormond Street Hospital, Institute of Child Health (UCL), EMA, Aparito.
PA to CEO
Following the agreement with AstraZeneca we will be working to speed up the progress of treatments and plan the clinical development of therapies in the following two areas:
- — Male infertility
- — Renal transplant
For investor enquiries please contact Zoe Hollowood
In addition, we will be working to progress treatments for the following conditions:
- — Pulmonary hypertension
- — Spinal cord injury
- — Nonalcoholic Steatohepatitis
- — Sickle cell disease
- — Glioma
- — DME
- — Pulmonary sarcoidosis
Covid-19 Trial Update - 04-01-21
Approval Received to Begin Recruiting in Czech Republic and Romania
The ARCADIA clinical trial is a randomised, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes and admitted to hospital with COVID-19. The trial, which is sponsored by the UK charity St George Street, has successfully recruited 50 of the planned 150 patients across 11 UK hospital sites over the past 3 months. To help ensure timely completion of study enrolment, the ARCADIA trial is now expanding with the addition of approximately 23 new hospital sites over the coming weeks. In addition to 4 new sites in the UK, up to 19 sites are to be opened in Czech Republic and Romania. Regulatory and ethics committee approval for both new countries was received at the end of December 2020 and the first patients from Czech Republic and Romania are expected to be recruited to ARCADIA before the end of January 2021.
Both Czech Republic and Romania have a high prevalence of diabetes (10.2% and 8.8% of the population having diabetes respectively), this compares with around 6.5% of people in the UK. In addition, both countries have regularly reported over 100 deaths from COVID-19 per day throughout December, indicating a high unmet clinical need.
The decision and rapid action to obtain approval in Romania and Czech Republic is testament to the strength of the St George Street team and its collaborative relationships with its development partners. St George Street is delighted to have received such rapid regulatory approval in the two new countries and looks forward to collaborating closely with the investigational teams in both countries.
The mechanism of actions of AZD1656, both blood glucose lowering and potential immunomodulatory action, are independent of viral mutations. AZD1656 activates glucokinase, which is expected to increase the migration of T regulatory cells in addition to reducing blood glucose. Reducing hyperglycaemia (high blood glucose) is increasingly seen to be important to improve outcomes in people with diabetes and COVID-19. Migration of regulatory T cells is expected to dampen down the hyperinflammation seen in the lungs for instance, that results in severe COVID-19.
Dave Tapolczay, CEO of St George Street said ‘I am delighted with the progress of the ARCADIA trial so far in the UK and through adding an additional 23 hospital sites we expect to see a significant impact on patient recruitment of the trial. Credit must go to the team in obtaining regulatory approval so quickly in Czech Republic and Romania. As a society we will need many solutions to battle the surging pandemic and I am proud that here at St George Street we are playing our part in helping to find those solutions.’
TRIAL INITIATED TO TEST POTENTIAL NEW COVID-19 TREATMENT FUNDED BY UKRI GRANT AND EML
A new therapy that could treat people with diabetes suffering from COVID-19 is to undergo an advanced clinical trial in the UK.
The Medicines and Healthcare products Agency (MHRA) has approved the trial following new preclinical research that suggests a glucose kinase activator (AZD1656) could help diabetes sufferers infected with coronavirus by dampening the overactive response of the immune system typically acute in those patients with raised blood glucose levels. The trial will involve hospitalised patients with mild to moderate COVID-19 symptoms and if successful the compound could ultimately be prescribed by a GP for people with diabetes presenting with early COVID symptoms.
People living with diabetes face a significantly higher risk of dying with COVID-19. One in three of all deaths with COVID-19 in hospital in England have been associated with diabetes. Diabetes, whether type 1 or 2, has been the leading single cause of co-morbidity during this pandemic. People living with type 1 diabetes are at three and a half times the risk, and people living with type 2 diabetes are at double the risk of dying in hospital with the virus compared to people without diabetes. Learn more.
This exciting new development, believed to be unique among the hundreds of COVID-related research projects around the world today, was arranged and structured by Professor Sir Chris Evans, Chairman and CEO of Excalibur Healthcare Services, through a new vehicle, Excalibur Medicines Ltd, which brought together the scientific intellectual property, international funding and a world leading team to drive the project forward. The idea of investigating AZD1656 in this setting was conceived by Professor John Martin and his team at St George Street, a UK-based biomedical research charity. The drug was originally developed for another indication by Astra Zeneca, who have agreed to provide the drug substance for the trial, while St George Street will lead the clinical trial.
The trial, named ARCADIA, will commence with Professor Evans and the Excalibur team having sourced investment from Mubadala of Abu Dhabi, one of the world’s leading sovereign wealth funds, Excalibur itself and several high net worth individuals. This is in addition to funding secured from the UK Government through the UKRI / Innovate UK programme. This enables the trial to go ahead at speed in 150 patients over a 4 month timeframe at multiple sites in the UK.
Professor Evans said: “All of us supporting this trial recognise this drug has the potential to make a huge difference to people with diabetes who are unfortunate enough to contract coronavirus and we foresee a significant impact on the level of fatalities in the future. Treatments such as this could be vital as we are likely to be living with this horrific virus for some time to come.”
David Tapolczay, CEO St George Street, said: “Given the current crisis, we have paused all our current research programmes to focus totally on this clinical trial and evaluate this potentially life-saving new drug. Our charity was set up to accelerate the delivery of treatments to patients and this ethos is needed now more than ever before. We want to do everything in our power to ensure patients recover from this terrible virus.”
Professor John Martin, Chairman of the charity and Principal Investigator on the grant awarded by UKRI, said: “Novel research thinking in an interdisciplinary group combined with the drive of the charity and the excellent relationship we have with Astra Zeneca have produced the potential for a great therapeutic leap. This also has potential for non-diabetic patients with COVD-19.”
NOTES TO EDITORS
Mechanism of Action:
In many patients with severe reaction to coronavirus infection, an overreaction of the body’s own immune system can cause severe problems including damage to the lungs and heart. This leads to breathing problems that might necessitate intubation and ventilation. AZD1656 has been shown to activate the migration of T regulatory cells to sites of damaging inflammation in preclinical experiments. Migration of T regulatory cells amplifies the body’s own mechanism of damping down an inappropriate inflammatory overreaction. T regulatory cells are also very important in the tissue repair process. AZD1656 has already undergone Phase ll trials for use in type 2 diabetes and is also currently under clinical investigation for renal transplant rejection in the UK.
St George Street believes this research into T regulatory cells shows AZD1656 could be of potential benefit for people with diabetes who have COVID-19. In addition, AZD1656 has been proven to be effective in reducing blood glucose levels over a 4-month period in previous clinical studies. Blood glucose control is thought to be an important predictor of mortality, with research reporting that patients with diabetes with poor blood glucose control had a greater mortality from COVID-19 than those with good glucose control. Elevated blood glucose, for instance, can increase glucose levels in airway secretions which can lead to increased viral replication in the lungs. Hence the potential treatment could have a dual mode of action that would be particularly helpful for COVID-19 patients with diabetes. It also has a clean safety profile having been already in twenty-five trials for another indication in almost a thousand patients.
The initiation of this clinical trial forms part of an existing collaboration between St George Street and AstraZeneca as part of its Open Innovation programme (www.openinnovation.astrazeneca.com).
About AZD1656 (Glucokinase activator):
AZD1656 has been shown to be a potent, selective, activator of glucokinase and reduces plasma glucose levels in preclinical experiments and in diabetic patients over four months. AZD1656 has been studied in clinical trials as a single dose up to 180 mg and multiple doses to 150 mg twice-daily for 8 days in healthy volunteers, as well as alone and in combination with other blood glucose control agents in patients with diabetes at 200 mg daily for up to 6 months duration. In both healthy volunteers and patients with diabetes, no significant safety concerns were noted.
About St George Street:
St George Street is a biomedical research charity on a mission to fast-track clinical trials so we can get new treatments as quickly as possible to the people who need them. We apply bold new thinking to unlock the therapeutic potential of therapies and science currently sitting on the shelf in pharma. We are a new type of charity, sourcing investment to accelerate clinical trials, where new science shows great potential and where patients and clinicians are calling out for treatments. St George Street was established in 2017 and brings together a powerful mix of expertise, from investors and business managers to clinical scientists and researchers.
If you are a doctor treating hospitalised COVID-19 patients in the UK and would like information on how to take part in the study please contact email@example.com